S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:PRTKParatek Pharmaceuticals Price Target & Analyst Ratings

$4.72
+0.06 (+1.29 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.52
Now: $4.72
$4.78
50-Day Range
$4.30
MA: $4.82
$5.52
52-Week Range
$2.50
Now: $4.72
$5.89
Volume514,500 shs
Average Volume746,393 shs
Market Capitalization$203.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

Analyst Ratings

Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Paratek Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.50, suggesting that the stock has a possible upside of 291.95%. The high price target for PRTK is $36.00 and the low price target for PRTK is $6.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.50$18.50$17.20$17.33
Price Target Upside: 291.95% upside375.58% upside342.16% upside317.67% upside

Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2020WedbushReiterated RatingOutperformHigh
2/26/2020HC WainwrightReiterated RatingBuyLow
1/27/2020SVB LeerinkReiterated RatingOutperformLow
1/8/2020WBB SecuritiesInitiated CoverageBuy$6.00Medium
1/2/2020Canaccord GenuityInitiated CoverageBuy$14.00Low
12/18/2019BTIG ResearchSet Price TargetBuy$36.00N/A
5/9/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
10/3/2018GuggenheimSet Price TargetBuy$26.00High
8/27/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$13.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
3/2/2018Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$36.00High
3/2/2018UBS GroupDowngradeStrong-Buy ➝ OutperformHigh
10/24/2017Robert W. BairdReiterated RatingBuy$40.00N/A
(Data available from 7/15/2018 forward)
This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.